Yarrow Bioscience, Inc
YARW Healthcare Biotechnology
Yarrow Bioscience, Inc’s revenue for fiscal 2025 (year ended December 2025) was $570,000.00, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 40.6%, EPS grew 67.1% and free cash flow grew 81.6%, each against the same quarter a year earlier.
Follow YARW
Yarrow Bioscience, Inc (YARW) EV/Sales
As of 16 October 2026, Yarrow Bioscience, Inc (YARW) trades at a EV/Sales of 124×. Over the past ten years it has ranged from −21.4× (January 2024) to 374× (January 2025); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 110× | (62.87%) |
| FY2024 | 295× | — |
| FY2023 | −7.6× | — |
| FY2022 | 91.3× | 416.73% |
| FY2022 | 17.7× | (78.45%) |
| FY2021 | 82.0× | 832.87% |
| FY2021 | 8.8× | 2.89% |
| FY2020 | 8.5× | (58.52%) |
| FY2020 | 20.6× | (11.39%) |
| FY2019 | 23.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 149× | 0.29% |
| Mar 2026 | 148× | 35.30% |
| Dec 2025 | 110× | 18.89% |
| Sep 2025 | 92.2× | (55.03%) |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −35.1× |
| TRDA Entrada Therapeutics, Inc. compare | −8.3× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −4.0× |
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| SION Sionna Therapeutics, Inc. compare | n/m |
| STRO Sutro Biopharma, Inc. compare | 0.5× |
| ADCT ADC Therapeutics SA compare | 1.5× |
| ACOG Alpha Cognition Inc. compare | 9.0× |
| YARW Yarrow Bioscience, Inc | 124× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)